-
Nat Commun: The important role and therapeutic potential of PRAK in tumor metastasis
Time of Update: 2021-03-26
Knockout of the Prak gene will inhibit the distant metastasis of the tumor but will not affect the growth of the primary tumorIt is worth noting that the pharmacological inactivation of PRAK with clinically relevant inhibitors can reproduce the anti-metastatic effect of knocking out Prak, thus highlighting the therapeutic potential of targeting PRAK in the control of tumor metastasis.
-
Br J Cancer: A few cups of coffee or tea a day can improve the survival rate of breast cancer patients
Time of Update: 2021-03-26
The results showed that increased coffee intake after diagnosis was associated with a decrease in breast cancer-specific mortality: compared to non-drinkers, drinking more than 3 cups of coffee a day corresponds to a 25% reduction in the risk of death.
-
JCO: Tipifarnib is effective for recurrent and/or metastatic head and neck squamous cell carcinoma
Time of Update: 2021-03-26
The results showed that Tipifarnib has a significant effect on R/M mHRAS-HNSCC patients with HRAS mutations.
Although targeted therapy has recently been included in standard treatment, the prognosis of R/M HNSCC patients is still very poor, with an estimated median overall survival of 13-15 months.
-
Br J Cancer: ABCSG-34 clinical trial reveals the effect of neoadjuvant therapy on breast cancer
Time of Update: 2021-03-26
RCB 0/1 rate and pCR rate of patients with conventional and reverse chemotherapyAll in all, the results of the study revealed that pre-treatment with docetaxel did not improve chemotherapy activity or tolerability.
-
Br J Cancer: The prognostic value of preoperative systemic inflammatory response (SIR) measurement in colon cancer patients
Time of Update: 2021-03-26
In summary, the results of the study show that for patients with colon cancer undergoing radical surgery, the SIG score combined with mGPS and NLR before surgery can better determine the patient's SIR response.
-
Br J Cancer: The added value of H2 antagonist ranitidine during paclitaxel treatment
Time of Update: 2021-03-26
Prevention This study aims to compare the incidence of HSR reactions between standard regimens including ranitidine and regimens without ranitidine during paclitaxel treatment.
This study aims to compare the incidence of HSR reactions between standard regimens including ranitidine and regimens without ranitidine during paclitaxel treatment.
-
2021 SGO | Are genomically unstable tumors more sensitive to immune checkpoint inhibitors?
Time of Update: 2021-03-26
The IMagyn050 study was stratified according to the expression status of BRCA1/2, HRD and PD-L1, and explored the efficacy of immune checkpoint inhibitors in patients with genomically unstable tumors.
Regardless of BRCA1/2 mutation or HRD status, CPB+atelizumab cannot improve PFS.
-
Br J Cancer: Whole genome analysis reveals the role of statins in colorectal cancer
Time of Update: 2021-03-26
All in all, the results of the study revealed that statins can induce BMP-specific activation of PTEN and inhibit the PI3K/Akt/mTOR signal transduction pathway in CRC.
-
PNAS analysis! Develop a new type of cancer immunotherapy that can target common genetic mutations!
Time of Update: 2021-03-26
PNAS scientists from Johns Hopkins University School of Medicine and other institutions have developed a new type of cancer immunotherapy prototype through research, which may be able to engineer T cells to target all common genetic mutations in cancer ( genetic alteration); this new method can stimulate the body's immune response to resist cells that lack a copy of a gene, that is, cells with loss of heterozygosity (LOH).
-
Science: Major development of CAR-T cells that recognize the expression level of protein antigens on the surface of cancer cells, which is expected to be used in the treatment of solid tumors
Time of Update: 2021-03-26
Anna Mäkelä, a postdoctoral researcher in the Saksela laboratory, is coordinating a project funded by the Finnish Academy of Sciences to study the application of CAR-T cell therapy on various cancer types and their surface structures.
-
Br J Cancer: Autoimmunity induced by immune checkpoint blocking therapy is related to the prognosis of metastatic melanoma and a unique T cell expression profile
Time of Update: 2021-03-26
All in all, the results of this study show that the early occurrence of irAE after ICB treatment is related to the better survival of MM patients.
The early occurrence of irAE after ICB treatment is related to the better survival of MM patients.
-
Nature: Bacteria may contribute to the anti-cancer immune response
Time of Update: 2021-03-26
The key new discovery is that these peptides are displayed on the surface of cancer cells by HLA protein complexes-these complexes exist on the membranes of all cells in our body and play a role in regulating immune responses.
-
CAR-M therapy is first used in human research
Time of Update: 2021-03-26
A few days ago, Carisma Therapeutics announced that it has completed the first patient administration of its chimeric antigen receptor macrophage (CAR-M) therapy CT-0508 in a phase I multi-center clinical trial.
-
Nat Commun: The clonal structure of malignant pleural mesothelioma can be used as a prognostic indicator and affect the tumor microenvironment
Time of Update: 2021-03-26
The results of this study reveal the potential evolutionary bottleneck of druggable drugs in MPM, as well as the influence of clonal structure on the shaping of the immune pattern, and may determine the clinical response to immune checkpoint suppression.
-
Nature: Liver cancer patients with underlying liver disease do not respond to immunotherapy
Time of Update: 2021-03-26
March 26, 2021 //---According to a recent study published in the journal Nature, immunotherapy is not only significantly ineffective for liver cancer patients who had previously suffered from non-alcoholic steatohepatitis (NASH), but it actually seems Promote the growth of tumors.
-
CAR-T bitter journey
Time of Update: 2021-03-26
At the same time, solid tumors lack chemokines (expressed at low levels in solid tumors) that can drive CAR-T cells to migrate to target cells.
The above obstacles make even CAR-T cells in After finding the target, it is also difficult to penetrate into the tumor tissue.
-
Professor Xu Wei: Diagnosis and Differential Diagnosis of CLL | The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-03-26
) The International Chronic Lymphocytic Leukemia Working Group (iwCLL) "Chronic Lymphocytic Leukemia Diagnosis, Treatment Indications, Efficacy Evaluation and Supportive Treatment Guidelines (2018 version)” pointed out: Regardless of the number of peripheral blood B lymphocytes or lymph node involvement, cytopenias caused by typical bone marrow infiltration are diagnosed as CLL.
-
Br J Cancer: Olaparib combined with hemi-thoracic radiotherapy to improve the therapeutic index of lung cancer
Time of Update: 2021-03-26
The purpose of this study is to explore the therapeutic index of olaparib combined with hemi-thoracic radiotherapy in a mouse lung cancer model induced by urethane.
The purpose of this study is to explore the therapeutic index of olaparib combined with hemi-thoracic radiotherapy in a mouse lung cancer model induced by urethane.
-
20% of nasopharyngeal cancer patients face recurrence and metastasis, immunotherapy may become a new "life-saving" method
Time of Update: 2021-03-26
Professor Hu Chaosu said that with the popularization of intensity-modulated radiotherapy and the application of comprehensive treatment, chemotherapy and the comprehensive application of targeted drugs, the five-year survival rate of nasopharyngeal cancer patients is as high as 80 % Above, compared with other malignant tumors, the curative effect is amazing.
-
New natural enemy of tumor? New antigen vaccine clinical trials are underway
Time of Update: 2021-03-26
Ott and his colleague Eryn Blass from the Dana Farber Cancer Institute in Boston, USA published an article entitled "Advances in the development of personalized neoantigen-based therapeutic" in Nature Reviews-Clinical Oncology.
Personalized neoantigen-based vaccination has the potential to induce long-lasting tumor-specific memory T cell populations.
